Fresenius Kabi Introduces Cancer Copay Scheme For Generics
Some Patients Could Find Their Monthly Costs Entirely Eliminated
Executive Summary
German pharma giant Fresenius Kabi has introduced a copay scheme for a number of its generic oncology medicines in the US, which could completely eliminate monthly costs for certain patients.
You may also be interested in...
Fresenius Kabi Takes On Drug Shortages With Iodixanol Launch
Fresenius Kabi has launched a generic iodixanol injection in the US, at a time when the drug is subject to a nationwide shortage. At the same time, the firm has introduced the country’s first Istodax rival.
Fresenius And Aurobindo Among Fresh Velcade Challengers In US
Multiple firms have launched bortezomib products for subcutaneous administration in the US, adding to competition on Takeda’s Velcade brand.
Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars
Fresenius Kabi has made a major move to bolster its biosimilars business by acquiring a majority 55% stake in mAbxience, with the purchase price comprising €495m upfront as well as subsequent milestone payments. The deal offers Fresenius not only enhanced biosimilars capabilities but also access to the expanding biologics CDMO market.